Education
About Us
Working with TipRanks
Follow Us
PureTech Health PLC (GB:PRTC)
LSE:PRTC
Earnings Data
Report Date
Aug 27, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-15.33Last Year’s EPS
-11.27Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: -2.23%
|Next Earnings Date:Aug 27, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted several significant achievements, including successful clinical trials and strong financial execution, but also revealed challenges related to market valuation and funding for future trials.Company Guidance
During the PureTech Health 2024 Year End Financial Results Conference, the company provided guidance on its strategic priorities and financial outlook, highlighting key metrics and achievements. As of March 31, 2025, PureTech reported approximately $339.1 million in cash at the PureTech level, supporting its efficient hub-and-spoke R&D model. In 2024, its founded entities raised $397.5 million, with over 88% from third-party investors, and generated $327.4 million in proceeds from monetization events. The company returned $100 million to shareholders via a tender offer and reported a consolidated net income of $27.8 million for 2024, driven by a $151.8 million gain from the deconsolidation of Seaport. Looking ahead, PureTech plans to discuss the Phase 3 pathway for its IPF treatment, deupirfenidone, with the FDA by Q3 2025 and initiate a Phase 3 trial by year-end, while exploring various funding mechanisms to support this effort.Phase 2b Trial Success for Deupirfenidone
Unprecedented results from PureTech's successful Phase 2b trial of deupirfenidone for Idiopathic Pulmonary Fibrosis (IPF), showing potential to stabilize lung function decline over 52 weeks.
FDA Approval of COBENFY
FDA approval of COBENFY for the treatment of schizophrenia in adults, marking a major validation for PureTech's scientific foundation.
Strong Financial Position
PureTech ended 2024 with cash, cash equivalents, and short-term investments of $366.8 million, ensuring financial runway into 2027.
Successful Fundraising by Founded Entities
Founded entities raised $397.5 million in 2024, with over 88% from third-party investors, supporting PureTech's hub-and-spoke R&D model.
Positive Clinical Data for LYT-200
LYT-200 showed favorable tolerability and evidence of clinical efficacy in a Phase 1b trial for AML and MDS, with six complete responses achieved.
---
GB:PRTC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:PRTC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 30, 2025 | 125.80p | 123.00p | -2.23% |
| Aug 28, 2024 | 165.00p | 169.60p | +2.79% |
| Apr 25, 2024 | 212.50p | 212.50p | 0.00% |
| Aug 29, 2023 | 185.60p | 193.00p | +3.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does PureTech Health PLC (GB:PRTC) report earnings?
PureTech Health PLC (GB:PRTC) is schdueled to report earning on Aug 27, 2025, TBA Not Confirmed.
What is PureTech Health PLC (GB:PRTC) earnings time?
PureTech Health PLC (GB:PRTC) earnings time is at Aug 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of PureTech Health PLC stock?
The P/E ratio of PureTech Health is N/A.
What is GB:PRTC EPS forecast?
GB:PRTC EPS forecast for the fiscal quarter 2025 (Q2) is -15.33.
---